Basem Goueli MD/PhD/MBA

CEO and founder at CancerLight  


Dr. Goueli has directed three independent cancer institutes, collectively representing 17 hospitals and 12 cancer centers. He is a hematologist and medical oncologist who has been the institutional principal investigator on nearly 100 clinical trials involving breast cancer, myeloma, prostate cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, myelodysplastic syndrome, CLL, DLBCL, esophageal cancer, etc. He is board-certified in hematology, medical oncology, internal medicine, and artificial intelligence in medicine.

Dr. Goueli's training includes:

MD: Mayo Clinic
PhD in biochemistry: Mayo Clinic
MBA: University of North Carolina, Chapel Hill
Internal Medicine Residency: George Washington University Hospital with 4 months at the NIH
Hematology/Oncology Clinical Fellowship: Stanford
Biochemistry Post-Doctoral Fellowship: Stanford
MIT Xpro Course Certificate: Designing Artificial Intelligence Products
MIT Xpro: Course Certificate: Robotics Essentials
MIT Xpro: Course Certificate: Drug and Medical Device Development
MIT Professional Education Course Certificate: Applied Data Science Bootcamp

Dr. Goueli resisted the trend toward subspecialization during his career as he felt ideation often happens at the level of the forest, not the trees. It's his firm belief many of the greatest future innovations will be at the interface of various disciplines.

Dr. Goueli's area of clinical expertise is precision medicine, and his ability to treat patients in all hematology/medical oncology disciplines uniquely positions him to sequence molecular-based therapies in the context of conventional therapy and clinical trials.

Dr. Goueli is the CEO and Founder of two companies, CancerClarity and CancerLight. They are early in development and hope to disrupt the clinical trial, patient education, and clinical care forums. Aside from running his two companies, Dr. Goueli is consulting medical director and medical monitor for 3 phase 1 Xbiotech clinical trials, consults for numerous other pharmaceutical companies, and sees patients full-time in the clinic as a hematologist/medical oncologist.

Contributing Author   in
The Insider's Guide to Translational Medicine  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Basem


Quarterbacking a Patient's Fight Against Cancer

  
Quarterbacking a Patient's Fight Against Cancer

In the incredibly competitive world of drug development, comprehensive precision, and healthtech, every strategic control point is essential. Over the next several months, during this editorial series, we will admittedly push the envelope as we elucidate several strategic control points …

Drowning in Data: A Data Science Primer for a Translational Scientist

  
Drowning in Data: A Data Science Primer for a Translational Scientist

In 1945 the volume of human knowledge doubled every 25 years. Now, that number is 12 hours [1]. With our collective computational power rapidly increasing, vast amounts of data and our ability to assimilate it, has seeded unprecedented fertile ground …

Choosing Cancer Weapons With the Best Aim

  
Choosing Cancer Weapons With the Best Aim

In oncology, we do the best we can. We give drugs with 10-20% chances of working because we have nothing else. Drugs are approved, right or wrong, based on mere weeks of overall survival benefit. Clinical trials labeled as novel …